J&J/DePuy Recalls ASR Hip Systems - Effort Could Cost $1.2 Bil.
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson subsidiary DePuy Orthopaedics is recalling all of its ASR hip resurfacing and ASR XL acetabular hip replacement systems worldwide due to elevated rates of revision surgeries to replace the devices, the company said Aug. 26
You may also be interested in...
FDA Advisory Panel Debates Science On Human Adverse Biological Reactions To Metal-Containing Devices
US FDA scientists and immunological experts discussed the latest science regarding patients’ biological reactions to metal implants and mercury in dental amalgam at a 13-14 November agency advisory committee meeting. The get-together was held to determine what additional actions the FDA can take to make sure certain patients are protected from immunological risks of the implants. The panel ultimately backed a transition away from mercury amalgam dental fillings and pushed for more research into risks associated with metal implants.
PMAs Are The New Reality For Metal-On-Metal Hips
A final order from FDA calls for manufacturers to submit PMAs or take their metal-on-metal hip devices off the market by May 18. The widely anticipated move is part of a broader response to elevated adverse event rates tied to the products.
DePuy’s Faulty Hip Replacement Shadow Lingers As India Issues Recall
The device manufacturer is under increasing regulatory pressure on the measures it took to inform patients or reimburse for tests and revision surgeries.